DBV Technologies SA (NASDAQ:DBVT) is advancing its VIASKIN Peanut program—completing toddler safety recruitment, starting infant studies and targeting a BLA submission with priority review in Q3 2026—while operating with $174.9M cash and funding into Q3 2027 despite a H1 2026 net loss of $98M.
Previous Week Recap
- DBV Targets BLA Submission For VIASKIN: DBV Technologies (DBVT) targets BLA submission for VIASKIN Peanut in Q3 2026 with priority review, secured funding through Q3 2027, completed toddler safety recruitment and initiated infant studies
- DBV Posts H1 2026 Net Loss: DBV Technologies (DBVT) posted a H1 2026 net loss of $98M and held $174.9M cash, funding operations through Q3 2027.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.